Rubius Therapeutics Inc

Company Profile

Rubius Therapeutics Inc had its IPO on 2018-07-18 under the ticker symbol RUBY.

The company operates in the Healthcare sector and Biotechnology industry. Rubius Therapeutics Inc has a staff strength of 6 employees.

Stock update

Shares of Rubius Therapeutics Inc opened at $0.02 at the start of the last trading session i.e. 2023-05-28.

The stocks traded within a range of $0.02 - $0.02, and closed at $0.02.

This is a +17.92% increase from the previous day's closing price.

A total volume of 57,661 shares were traded at the close of the day’s session.

In the last one week, shares of Rubius Therapeutics Inc have increased by +9.68%.

Rubius Therapeutics Inc's Key Ratios

Rubius Therapeutics Inc has a market cap of $1.85 million, indicating a price to book ratio of 0.4199 and a price to sales ratio of 0.

In the last 12-months Rubius Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-120995000. The EBITDA ratio measures Rubius Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Rubius Therapeutics Inc’s operating margin was 0% while its return on assets stood at -46.63% with a return of equity of -185.31%.

In Q4, Rubius Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Rubius Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-2.35 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Rubius Therapeutics Inc’s profitability.

Rubius Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.1116. Its price to sales ratio in the trailing 12-months stood at 0.

Rubius Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$23.07 million

Total Liabilities

$7.94 million

Operating Cash Flow

$0

Capital Expenditure

$266000

Dividend Payout Ratio

0%

Rubius Therapeutics Inc ended 2023 with $23.07 million in total assets and $0 in total liabilities. Its intangible assets were valued at $23.07 million while shareholder equity stood at $15.13 million.

Rubius Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $7.94 million in other current liabilities, 90000.00 in common stock, $-856684000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $14.87 million and cash and short-term investments were $18.94 million. The company’s total short-term debt was $1,100,000 while long-term debt stood at $0.

Rubius Therapeutics Inc’s total current assets stands at $20.20 million while long-term investments were $0 and short-term investments were $4.07 million. Its net receivables were $0 compared to accounts payable of $1.23 million and inventory worth $0.

In 2023, Rubius Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $266000.

Comparatively, Rubius Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$0.02

52-Week High

$1.57

52-Week Low

$0.013

Analyst Target Price

$1

Rubius Therapeutics Inc stock is currently trading at $0.02 per share. It touched a 52-week high of $1.57 and a 52-week low of $1.57. Analysts tracking the stock have a 12-month average target price of $1.

Its 50-day moving average was $0.02 and 200-day moving average was $0.27 The short ratio stood at 0.49 indicating a short percent outstanding of 0%.

Around 549.8% of the company’s stock are held by insiders while 5368.8% are held by institutions.